Source: FierceBiotechIT

Nerre Therapeutics: GSK spinout bags £23M to take NK antagonists into phase 2

GSK spinout bags £23M to take NK antagonists into phase 2 nick.paul.taylor Wed, 01/04/2017 - 11:36

Read full article »

Nerre Therapeutics's Competitors | Nerre Therapeutics's News | Nerre Therapeutics's Financials

Followers on Owler

Est. Annual Revenue

$100K-5.0M

Est. Employees

1-25

CEO

Mary Kerr

CEO Approval Rating

73/100

Nerre is an England-based clinical-stage pharmaceutical company that researches and develops neurokinin receptor antagonist drugs to treat cough hypersensitivity disorders.